Genentech

For more than 40 years, we’ve worked with American Cancer Society to help expand access to quality cancer care, clinical trials and resources for all people impacted by cancer. Together, we’ve helped enable more than 1.4 million new screenings, and we know there is still more work to do to ensure that everyone can receive the care they need and deserve. Learn more about how we are working to remove barriers to screenings and treatment: http://spr.ly/6041NN4s7 #ASCO25

#Breaking: Today we presented two-year data from our investigational BTK inhibitor Phase II open-label extension study for people living with relapsing multiple sclerosis (RMS) at the #CMSC2025 Annual Meeting. Learn more about our efforts to advance research and develop new treatment options for people living with the condition: http://spr.ly/6046N4sRy

In Episode 1 of our new #InTheLab series, Principal Scientist Alecia Dent visited Senior Scientist Scott Peruski’s lab bench to explore how his team is pioneering new obesity treatments targeting GLP-1. Go behind the scenes of the latest in obesity research, and learn more about this topic in Season 6, Episode 1 of our podcast, Two Scientists Walk into a Bar. http://spr.ly/6040NFvxo

At #ASCO25, we're presenting two-year follow-up data from our Phase III study, demonstrating that our CD20xCD3 bispecific antibody combined with chemotherapy continues to show a clinically meaningful improvement in overall survival for certain people with relapsed or refractory diffuse large B-cell #lymphoma. This data further reinforces the potential in this patient population. Learn more: https://lnkd.in/d-KQb_XX 

The FDA approved a third indication for our ophthalmology treatment, now available to people living with #DiabeticRetinopathy – a leading cause of vision loss. Learn about our commitment to offering treatment that may protect vision in people with this diabetic eye disease: http://spr.ly/6046NaEWj

In S6E02 of Two Scientists Walk Into a Bar, our Director of Biological Research and AI Development, Tommaso Biancalani and Director of Infectious Diseases in Research Biology, Steven Rutherford join co-host Danielle Mandikian to discuss how scientists are harnessing AI to help uncover the hidden corners of the chemical space and identify novel antibiotics. Tune in now to learn what's next in the fight against antibiotic resistance. http://spr.ly/6048NvrzA

Last week, Aviv Regev, our Head of Research and Early Development, took the stage at the #STATBreakthrough West summit with STAT's Matthew Herper to share how we’re harnessing artificial intelligence to transform the way we discover and develop new medicines. When asked where AI is headed in the future for drug discovery, Aviv said we will see a major shift in how labs operate with AI-driven automation. As Aviv shared, “you will absolutely need the grad students, the postdocs, the scientists at all levels. None of this is going away, but the capacity is going to be a lot higher.” Watch more of Aviv’s talk below:

Congratulations to Bea Lavery, our Vice President of Regulatory Strategy, for being named to The Medicine Maker Power List! From growing up in a farming community in Alberta, to helping shape the future of clinical research, Bea’s journey reflects the power of scientific curiosity, purpose-driven work and bold, inclusive leadership. We’re proud to celebrate her recognition as an inspirational and innovative leader in advancing science and patient impact. Read Bea’s full Q&A here: http://spr.ly/6049NYHJ1

We’re proud to share that Dr. Robert Wood from Johns Hopkins Children's Center was recently named to the 2025 TIME100 Health list by TIME for his leadership in food allergy research. As lead investigator on the Phase 3 study that supported the FDA approval of our medicine for food allergies, Dr. Wood helped pave the way for a new approach to treatment. We’re honored to recognize this milestone and to be part of the continued progress bringing hope to the millions affected by food allergies. #FoodAllergyAwareness #FoodAllergies #TIME100HEALTH

Congratulations to Shannon Turley, our Vice President and Senior Fellow in Immunology and Regenerative Medicine, who was recently elected as a new member of the National Academy of Sciences. This prestigious honor recognizes Shannon’s outstanding scientific achievements in immunology, oncology and stromal cell biology.